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Since human Nucleoside Transporters (hNTs) were identified by their activity as transport
systems, extensive work has been done to fully characterize them at the molecular
and physiological level. Many efforts have been addressed to the identification of their
selectivity for natural substrates and nucleoside analogs used to treat several diseases.
hNTs belong to two different gene families, SLC28 and SLC29, encoding human
Concentrative Nucleoside Transporters (hCNTs) and human Equilibrative Nucleoside
Transporters (hENTs), respectively. hCNTs and hENTs are integral membrane proteins,
albeit structurally unrelated. Both families share common features as substrate selectivity
and often tissue localization. This apparent biological redundancy may anticipate some
different roles for hCNTs and hENTs in cell physiology. Thus, hENTs may have a
major role in maintaining nucleoside homeostasis, whereas hCNTs could contribute to
nucleoside sensing and signal transduction. In this sense, the ascription of hCNT1 to
a transceptor reinforces this hypothesis. Moreover, some evidences could suggest a
putative role of hCNT2 and hCNT3 as transceptors. The interacting proteins identified
for hCNT2 suggest a link to energy metabolism. Moreover, the ability of hCNT2 and
hCNT3 to transport adenosine links both proteins to purinergic signaling. On the other
hand, the broad selectivity transporters hENTs have a crucial role in salvage pathways
and purinergic signaling by means of nucleoside pools regulation. In particular, the two
new hENT2 isoforms recently described together with hENT2 seem to be key elements
controlling nucleoside and nucleotide pools for DNA synthesis. This review focuses on
all these NTs functions beyond their mere translocation ability.
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INTRODUCTION
The first human Nucleoside Transporter (hNT) protein was identified and cloned more than
20 years ago. In a few more years, the whole panel of hNTs was fully unveiled (Griffiths et al.,
1997a,b; Ritzel et al., 1997, 1998, 2001; Acimovic and Coe, 2002; Baldwin et al., 2004). Since then,
the study of these proteins has mostly focused on the identification of their substrate selectivity and
specificity, their structural determinants and their tissue and subcellular localization.
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hNTs are encoded by genes belonging to two different
SoLute Carrier (SLC) families, SLC28 and SLC29. SLC28
include the three members of the human Concentrative
Nucleoside Transporter (hCNT1, 2 and 3) family, whereas
SLC29 comprises the four members of the human Equilibrative
Nucleoside Transporter (hENT1, 2, 3, and 4) family. NTs are
integral membrane proteins, albeit the CNTs and ENTs are
structurally unrelated. NTs, or at least some of them, are
physiologically relevant mainly due to their likely role in the
salvage pathway of natural nucleosides. Moreover, their ability
to transport nucleoside analogs currently used as drugs to treat
several diseases has also stimulated research on hNTs in the
pharmacological field.
In the last few years, several studies on NT biology have
contributed to change the focus on these proteins, shifting from
the analysis of their role as mere substrate translocators to more
diverse functions in cell physiology. The possibility of hCNT
showing transceptor functions will be discussed, along with other
roles particular NT subtypes can play in cell biology. Overall they
support the view that new roles for nucleoside transporters are
emerging.
NTS AS SUBSTRATE TRANSLOCATORS
Concentrative Nucleoside Transporters
CNTs mediate the unidirectional uptake of nucleosides coupled
to the influx of sodium ions, albeit CNT3 can also accept protons.
The sodium/nucleoside coupling ratio is 1:1 for CNT1 and CNT2
and 2:1 for CNT3. The three members also differ among them
in their substrate selectivity, except for uridine, which can be
transported by all subtypes. CNT1 transports pyrimidines and
CNT2 carries purines, whereas CNT3 mediates the uptake of
both purines and pyrimidines (Figure 1A). The basic biochemical
properties (i.e, substrate selectivity and specificity) of NTs have
been recently reviewed and summarized elsewhere (Young et al.,
2013; Young, 2016; Pastor-Anglada et al., 2018).
hCNTs were initially thought to be restrictively expressed
in polarized epithelia, although their expression appears
considerably broader than expected. These proteins present a
preferential localization at the apical side of polarized epithelia
in contrast to ENT proteins, thereby favoring nucleoside
transepithelial flux (Mangravite et al., 2001, 2003; Lai et al., 2002;
Errasti-Murugarren et al., 2007).
Equilibrative Nucleoside Transporters
ENTs mediate the facilitative transport of nucleosides and
some of them also transport nucleobases, albeit with different
specificity. Except for ENT4, ENT proteins have a broad
permeant selectivity and are able to transport both purines and
pyrimidines (Figure 1B) (Young et al., 2013; Pastor-Anglada
et al., 2018). These three transporters differ among them by
nucleoside specificity although, in general, ENTs present lower
affinity for their substrates than the CNT family members. ENT1-
3 are widely distributed in different cell types and tissues, even
though ENT3 is located at intracellular membranes, mostly
in lysosomes but also in mitochondria (Baldwin et al., 2005;
Govindarajan et al., 2009). ENT4 is evolutionarily divergent from
ENT1-3 and it cannot be considered a conventional nucleoside
transporter. In fact, it was originally described as a polyspecific
organic cation transporter (Engel et al., 2004), even though it
transports adenosine at low extracellular pH (Barnes et al., 2006).
The possibility of intracellular pH regulating adenosine transport
via hENT1 and hENT2 proteins has been recently reported in
HUVECs (Celis et al., 2017).
NTS BEYOND TRANSPORT
Both nucleoside transporter families share common features and
are often expressed in the same cell types and tissues. It is worth
mentioning that ENTs are bidirectional transporters whereas
CNTs are not. Moreover, their different substrate specificity
and mode of action might support different and probably
complementary roles in modulating nucleoside bioavailability.
Nevertheless, it also appears that there might be some apparent
biological redundancy. This could be associated with additional
specific functions and/or diverse regulatory roles for the different
NT protein subtypes. In this sense, it can be hypothesized that
ENTs might be related to metabolic homeostasis whereas CNTs
may be associated with more specialized functions, such as
nucleoside sensing and signal transduction.
The hCNT1 Transceptor
The transceptor concept was presented for the first time by Johan
Thevelein back in 1999 in the course of the 14th Small Meeting
of Yeast Transport and Energetics (SMYTE) held in Cordoba
(Spain) (Diallinas, 2017), although findings supporting this
concept were published later (Donaton et al., 2003). Thevelein
and colleagues are also reviewing the state of the art of this topic
in this issue. The studies of the general amino acid permease
Gap1 of Saccharomyces cerevisiae evidenced that Gap1 combined
transporter and receptor functions (Donaton et al., 2003; Rubio-
Texeira et al., 2010). The coexistence of these two functions
within the same protein led to coin the word “transceptor” (from
transporter and receptor contraction). Since then, several high
affinity solute transporter proteins have been demonstrated to fit
under the transceptor concept. In this context, considering the
overlapping selectivity and the frequent redundant localization
of Equilibrative and Concentrative Nucleoside Transporters, the
high affinity CNTs seemed good candidates to be classified as
transceptors.
Recently, hCNT1 has been the first NT described as a
transceptor by our research group (Figure 2) (Pérez-Torras
et al., 2013). Considering NTs have a major role in determining
the bioavailability of several anticancer drugs, various studies
have been performed to analyze their expression in cancer.
In particular, it has been shown that hCNT1 expression is
highly reduced or even lost in different types of tumors (Farré
et al., 2004; Gloeckner-Hofmann et al., 2006; Lane et al.,
2010; Bhutia et al., 2011; Urtasun et al., 2017). Accordingly,
hCNT1 biological function (hCNT1-related transport activity)
is almost undetectable or null and its expression at the protein
and mRNA level is often lost or dramatically reduced in
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FIGURE 1 | Simplified scheme of hNT protein functions. (A) hCNT substrate selectivity and Na+-nucleoside coupling ratio. (B) hENT substrate selectivity and their
pharmacological inhibitors. Apparent affinity constants (µM) of NT substrates are shown in parenthesis. ND means Not Determined.
cancer derived cell lines. Actually, CNT1 is a highly regulated
protein (Valdés et al., 2002; Fernández-Veledo et al., 2004;
Podgorska et al., 2007; Klein et al., 2009) and its expression
has been associated with differentiation (Soler et al., 2001;
Soler et al., 2003). Interestingly, restitution of hCNT1 in
cancer cell lines provoked unexpected effects that could not be
explained by the mere increase in the uptake of pyrimidine
nucleosides. Although purine/pyrimidine unbalance can by itself
induce a variety of genotoxic effects (Mathews, 2015) the
biological impact of hCNT1 restitution, as discussed below, was
mimicked by the polymorphic variant hCNT1S546P which is
unable to translocate its substrates but appears to be properly
folded and inserted into the plasma membrane (Cano-Soldado
et al., 2012; Pérez-Torras et al., 2013). hCNT1 restoration in
pancreatic cancer derived cell lines significantly altered the
phosphorylation status of signal-transducing kinases related to
different pathways, reduced cell migration, cell cycle progression
and induced non-apoptotic cell death. Moreover, restoration
of hCNT1 significantly reduced tumor growth (Pérez-Torras
et al., 2013). All these observations, taken together, were crucial
to define hCNT1 as a transceptor. Although the physiological
relevance of hCNT1 as a transceptor protein is still being
studied in our laboratory, the variety of effects observed after
its restitution in a cancer background suggests that different
signaling pathways might be implicated in hCNT1-induced
biological effects, which we think might be, at least partially,
related to its interactome.
hCNT2 and hCNT3 as Putative
Transceptors
The two other members of the SLC28 gene family, hCNT2 and
hCNT3, have not been assigned yet as transceptors, although it
can be hypothesized they might be.
The study of the hCNT2 interactome allowed the
identification of two proteins related to energy metabolism.
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FIGURE 2 | The hCNT1 transceptor. hCNT1, as a result of substrate binding
is able to alternate from outward- to inward-facing conformations to allow the
translocation of pyrimidine nucleosides into the cell. Aside from the transporter
function of hCNT1, this protein is able to act as a nutrient transceptor with no
need to translocate. As a transceptor, hCNT1 has been involved in the
regulation of cell cycle, migration, cell death, and tumor growth.
Glucose-Regulated Protein 58 (GRP58) and aldolase B were
identified as hCNT2 partners using the N-terminus tail of
hCNT2 as bait (Huber-Ruano et al., 2010). The biological
functions of these partners could anticipate a regulatory model
dependent on cell nutrient bioavailability. In this sense, GRP58
expression increased in low glucose conditions, whereas hCNT2
expression and activity decreased. Moreover, glucose and fructose
availability increased the glycolytic flux and induced transient
interactions between aldolase B and hCNT2, which in turn were
associated with increased transport activity by a mechanism
compatible with transporter conformational changes (Huber-
Ruano et al., 2010). Moreover, purinergic modulation of CNT2
in hepatocytes is dependent upon glucose availability and KATP
channel function (Duflot et al., 2004). These observations suggest
that hCNT2 function is dependent upon energy metabolism,
although the possibility of hCNT2 function regulating aldolase B
activity by protein–protein interactions cannot be ruled out. To
some extent this would be consistent with a putative transceptor
role for hCNT2.
On the other hand, the purine nucleoside adenosine is
a multifaceted signaling molecule implicated in a variety of
physiological and pathophysiological processes. Both hCNT2 and
hCNT3 can also modulate cell biology by means of their ability
to regulate extracellular adenosine levels and consequently,
purinergic signaling. Although this role mainly relies on their
transporter activity, a sort of sensor function cannot be ruled
out in order to trigger the activation of specific signaling
pathways to regulate cell physiology. Indeed, as mentioned
above, CNT2 was shown to be under the Adenosine Receptor
1 (A1R) control in hepatocytes by a mechanism mediated
by the activation of ATP-sensitive K(+) channels, being the
extent of purinergic modulation affected by glucose availability
(Duflot et al., 2004). A similar crosstalk between CNT2 and
adenosine receptors was also been reported in neurons. Under
several adverse conditions characterized by increased adenosine
levels such as sleep deprivation and ischemia induced by an
experimental ictus, CNT2 expression was down-regulated in the
rat brain (Guillén-Gómez et al., 2004; Medina-Pulido et al., 2013).
Moreover, adenosine transported by CNT2 is able to trigger
AMPK activation in intestinal epithelial, liver parenchymal, and
neuronal cell models (Aymerich et al., 2006; Medina-Pulido et al.,
2013). The possibility of a single transporter protein mediating
both adenosine removal from the extracellular milieu and AMPK
signaling is consistent with the view that CNT2 is playing a
regulatory role in cell physiology beyond the mere salvage of
extracellular nucleosides.
Aside from CNT2, the other high affinity adenosine
transporter, CNT3, also contributes to the crosstalk regulation
between adenosine transporters and receptors. hCNT3 shows
broad expression in epithelial tissues albeit in some cases presents
a differential expression pattern to that reported for hCNT2.
hCNT3 is poorly expressed in normal hepatocytes, although it
is well represented in biliary epithelia, where it appears to be
the major player in extracellular adenosine levels regulation.
In cholangiocytes CNT3 is under purinergic regulation via
the Adenosine receptor 2A (A2AR), thereby contributing to
complete purinergic control of bile flow started by ATP secretion
into the bile (Godoy et al., 2014).
ENT2 in Cell Cycle Progression
The broad selectivity transporters ENTs, contrary to CNTs, are
widely distributed in all tissues. This feature could suggest a
main role of ENTs in salvage pathways required to maintain
the nucleoside and nucleotide pools. Indeed, as mentioned
above, it is not unlikely that CNT expression is lost in poorly
differentiated but highly proliferative cell types. In this regard,
the role of these membrane proteins (ENTs) would better fit with
the classical roles assumed to be played by most transporters.
This is the provision of substrates for either metabolic or
structural needs. Nevertheless, regulation of nucleoside and
nucleotide pools may also have regulatory relevance. Nucleos(-
t)ides are compartmentalized within cells into cytoplasmic and
nuclear pools, such amounts being different and dependent
on cell requirements (Khym et al., 1978; Bjursell and Skoog,
1980). Moreover, abnormalities in dNTP pool sizes determine
DNA replication fidelity and may contribute to mutagenic
processes related to carcinogenesis (reviewed in Mathews, 2015).
Interestingly, ENTs appeared later in the evolution, being only
restricted to eukaryotes which are defined by the presence
of nucleus and organelles surrounded by cell membranes.
NTs were initially considered to be predominantly plasma
membrane proteins (Endo et al., 2007). However, hENT2
and two novel nuclear smaller hENT2 isoforms generated by
differential splicing have recently been identified as key elements
controlling the nucleoside and nucleotide pool for effective
DNA synthesis and cell cycle progression (Grañé-Boladeras
et al., 2016). This new evidence clearly points to a model
where hENT2 and their isoforms are responsible for the rapid
supply of nucleotides required into the nucleus during DNA
replication.
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ENT1 and Adenosine Signaling in
Physiological and Pathophysiological
Conditions
As mentioned above, adenosine is an important component of
the purinergic signaling machinery. Considering that ENTs are
present in all tissues, including the Central Nervous System
(CNS), it is possible that they are members and potential
pharmacological targets of purinergic signaling in physiological
conditions. Adenosine signaling has been implicated in the
pathophysiology of many diseases and psychiatric disorders.
Alterations in the function of ENT subtypes able to transport
adenosine (mainly ENT1), have been associated with altered
adenosine levels thereby resulting in abnormal signaling likely
to contribute to several pathophysiological conditions. Mice
lacking ENT1 (Choi et al., 2004) have been a very useful model
to study the association of this transporter with adenosine
signaling. In this regard, owing to the ability of the other
ENTs to transport adenosine, their implication in adenosine
physiological functions and their pathophysiological alterations
cannot be discarded and deserves further research. In the CNS,
diminished ENT1, with regards to addictive disorders has been
directly associated with increased vulnerability to both goal-
directed behavior and excessive ethanol drinking (Choi et al.,
2004; Nam et al., 2011, 2013). Furthermore, impaired ENT1
expression and thus adenosine homeostasis results in a reduction
in glial fibrillary acidic protein (GFAP), excitatory amino acid
transporter type 2 (EAAT2) and aquaporin type 4 (AQP4)
expression, and alters astrocyte function (Wu et al., 2010, 2011;
Lee et al., 2013; Hinton et al., 2014a). Additionally, either
low levels or pharmacological inhibition of ENT1 contribute
to cardioprotection due to elevated adenosine circulating levels
(Rose et al., 2010; Ramadan et al., 2014). ENT1 has also been
associated to biomineralization disorders, its loss contributing
to reduced bone density (Hinton et al., 2014b) and to ectopic
mineralization of soft tissues (Warraich et al., 2013).
Regarding CNS, animal models and patient samples have
revealed that ENT1 and adenosine constitute biomarkers of the
initial stages of neurodegeneration in Huntington disease with
ENT1 transcript being significantly upregulated in those patients
(Guitart et al., 2016). Thus, ENT1 inhibition could be a potential
therapeutic target for treating Huntington disease (Guitart et al.,
2016, 2017; Kao et al., 2017).
NTS INTERACTOME
NTs have been often considered as independent entities at the
cell membrane with a unique function as nucleoside gatekeepers.
Nevertheless, a growing number of studies are contributing to
build up a new perspective of NT biology, which we think will
be, at least in part, explained by their interacting proteins and the
networks they might belong to.
Regarding hCNTs, as previously discussed, the two hCNT2
interacting proteins GRP58 and aldolase B, suggest a link between
this particular transporter subtype and energy metabolism
(Huber-Ruano et al., 2010). At this moment, these are the
most relevant, a priori biologically unrelated interacting proteins,
described for CNTs. Nevertheless, the transceptor role of hCNT1
would unveil the occurrence of unexpected interactions likely to
explain some of its biological actions beyond its mere role as a
nucleoside transporter protein. Some other reported interactors
will not help to explain putative transceptor functions but might
help to understand very basic biological phenomena responsible
for hCNT trafficking and turnover. That would be the case
for RS1 and galectin-4. The transporter regulator protein RS1
controls the abundance and activity of the three hCNT members
at the plasma membrane, particularly in polarized epithelia.
Although there is no biochemical evidence of direct interaction
between RS1 and selected transporter subtypes, it is highly
probable that common regulatory events implicating the three
proteins rely upon protein complexes where RS1 and hCNTs are
present. This regulatory function seems to be exclusively related
to trafficking events resulting in the down-regulation of these
proteins without any evident effect of RS1 at the transcriptional
level (Errasti-Murugarren et al., 2012). Interaction of hCNT3
with galectin-4 was described in colonic epithelial cells where this
partnership appears to be crucial for the proper insertion and
retention of this transporter at the apical membrane, determining
also hCNT3 turnover (Fernández-Calotti et al., 2016).
Concerning ENTs, the first set of putative ENT1 interactors
was identified using a variety of proteomic approaches and,
as can be anticipated for the CNTs, these interacting partners
include various types of proteins. Among them, calcium signaling
transducer calmodulin (CaM), the interactor already confirmed,
binds to the large intracellular loop of ENT1 in a calcium-
dependent manner (Bicket et al., 2016). In this case, the
interaction appeared to explain, at least in part, the calcium-
signaling-dependent regulation of nucleoside flux described for
neural cells (Zamzow et al., 2009; Wall and Dale, 2013). For
the other ENTs, only the interaction of ENT2 with its novel
spliced isoforms described above have been published, albeit
some interactors may also be envisaged.
NTS AND DISEASE
NTs are crucial to ensure nucleoside and nucleotide homeostasis
and due to the importance of these molecules in many
physiological processes it is easy to envisage that their alteration
may be behind some pathological conditions.
Cancer is the paradigm of a pathophysiological condition
characterized by abnormal high requirement of nucleotides
to support DNA synthesis associated to cell proliferation
and this may rely upon nucleoside salvage and, accordingly,
transport across the plasma membrane. Thus, changes in
NTs profile to fulfill nucleotide demand may be expected.
However, the situation seems to be more complex. Indeed,
expression of hCNT-type transporters is commonly associated
with differentiated cell lines and at least for hCNT1, oncogenesis
is often related to down-regulation of its expression (Farré et al.,
2004; Zollner et al., 2005; Lane et al., 2010; Bhutia et al., 2011;
Martinez-Becerra et al., 2012; Mohelnikova-Duchonova et al.,
2013). hCNT1 loss may be relevant considering it is a transceptor
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with additional functions that clearly point to a role in cell cycle
progression, migration, and cell death regulation (Pérez-Torras
et al., 2013). In contrast, nucleoside influx in cancer cells seems to
rely on ENT-type transporters. High levels of hENT2 expression
have been correlated with advanced stages in diverse tumor types
including hepatocellular carcinoma, mantle cell lymphoma, and
ovarian carcinoma (Hartmann et al., 2008; Chen et al., 2010; Bock
et al., 2012). Indeed, the role of hENT2 isoforms in sustaining
nucleotide availability to proliferate could explain in part this
association (Grañé-Boladeras et al., 2016). hENT1 studies are
more controversial due to the fact that the patient cohorts
used usually include treated patients, which makes it difficult to
discriminate between the impact of the treatment from the role
of hENT1 per se (Pastor-Anglada and Perez-Torras, 2015).
Nucleosides are semi-essential nutrients that can be absorbed
from the diet and in this sense the intestine is the first step in
their absorption. Inflammatory bowel diseases, such as Crohn’s,
show an altered pattern of several transporters, including NTs
(Wojtal et al., 2009; Pérez-Torras et al., 2016). The pyrimidine-
and purine-preferring transporters, hCNT1 and hCNT2 are
downregulated, whereas hENT1 is upregulated. Moreover, other
purinome members are also altered, reinforcing again the crucial
role of NTs in physiological networks (Pérez-Torras et al., 2016).
Moreover, some diseases such as diabetes, hypertension,
and pregnancy diseases involve altered adenosine transporter
function, basically associated with ENT activities (Pardo et al.,
2013; Salsoso et al., 2017; Sobrevia and Fredholm, 2017).
CONCLUSION
NTs have been extensively studied regarding their role as
substrate translocators. Indeed they were initially identified by
means of their nucleoside transport activity and classified as
“transport systems” (Oliver and Paterson, 1971; Pickard and
Paterson, 1972). Here we have briefly reviewed the state of
the art on the emerging roles of NTs. Current evidence shows
they may be active players regulating cell physiology instead
of mere nucleoside translocators. hCNTs may show transceptor
properties, already demonstrated for hCNT1 whereas ENTs
might regulate nucleoside pools and purinergic signaling.
These new roles and others to be discovered in the near future
will contribute to better understand the rationale for the apparent
biological redundancy of NT expression in most cells and tissues.
In this sense, NTs must be considered as members of cellular
networks relevant for various biological functions, a concept
which is likely to apply to many other SLC-encoded proteins.
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